ASCO 2020

American Society of Clinical Oncology 2020

At the 2020 ASCO virtual meeting, Boehringer Ingelheim presented the latest data on their cancer research program across multiple tumor types.

 

Please see below for more information and downloadable versions of our ASCO publications.

Friday 29 May – Tuesday 31 May
Virtual format
Publication

Browse through the publications below to learn more about our emerging data.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumor Type
  • All tumor types
Friday 29 May – Tuesday 31 May
Phase Ib study of BI 836880, a VEGF/Ang2 blocking nanobody, in combination with BI 754091, an anti-PD-1) antibody: initial results in patients with advanced NSCLC
Author(s): Girard et al.

Poster number: 332

e-Presentation
Tumor Type(s): non-small cell lung cancer (NSCLC)
Abstract Number: 9566
A Phase Ia/Ib, dose-escalation/expansion study of BI 907828 (an MDM2-p53 antagonist) in combination with BI 754091 (an anti-PD-1 antibody) and BI 754111 (a LAG-3 targeting antibody) in patients with advanced solid tumors
Author(s): Tolcher et al.

Poster number: 390

e-Presentation
Tumor Type(s): solid tumors
Abstract Number: TPS3660
A Phase I, open-label, dose escalation trial of BI 1701963 (a SOS1::KRAS interaction inhibitor) as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors
Author(s): Gort et al.

Poster number: 381

e-Presentation
Tumor Type(s): solid tumours
Abstract Number: TPS3651
An open label, Phase I trial of the anti-PD-1 antibody BI 754091 alone and in combination with BI 754111 (a LAG-3 targeting antibody) in Asian patients with advanced solid tumors
Author(s): Kang et al.

Poster number: 118

e-Presentation
Tumor Type(s): solid tumours
Abstract Number: 3054
Safety profile of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors
Author(s): Johnson et al.

Poster number: 127

e-Presentation
Tumor Type(s): solid tumours
Abstract Number: 3063
Nintedanib* + docetaxel in lung adenocarcinoma patients following treatment with ICIs: Updated efficacy and safety results of the ongoing non-interventional study VARGADO (NCT02392455)
Author(s): Grohé et al.

Poster number: 370

 

Click here for an audio recording by Professor Grohé, presenting the latest results from the VARGADO study

e-Presentation
Tumor Type(s): NSCLC
Abstract Number: 9604
Efficacy of afatinib** in clinical practice – final results of the GIDEON study in EGFR mutated NSCLC in Germany
Author(s): Brückl et al.
e-Presentation
Tumor Type(s): NSCLC
Abstract Number: e21636 (publication only)
Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer
Author(s): Huijberts et al.

Poster number: 343

e-Presentation
Tumor Type(s): CRC, NSCLC, Pancreatic cancer
Abstract Number: 3613
Implementing a novel method to estimate the ‘Burden of therapy’ (Both®) for patients with metastatic pancreatic cancer treated with gemcitabine plus afatinib versus gemcitabine in the AIO ACCEPT trial
Author(s): Haas et al.
e-Presentation
Tumor Type(s): Pancreatic cancer
Abstract Number: e16786 (publication only)
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

Pipeline compounds shown here are under pre-clinical and/or clinical investigation, and have not been approved. Their safety and efficacy have not been established.

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.

**Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

© 2020 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: June 2020